IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
Psoriasis
About this trial
This is an interventional treatment trial for Psoriasis
Eligibility Criteria
Inclusion Criteria: Have a diagnosis of plaque-type psoriasis for at least 6 months; Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND static Physician's Global Assessment (sPGA) score of 3 (moderate) or greater; Psoriasis covering at least 10% of body surface area; Must be a candidate for either systemic therapy or phototherapy for psoriasis. Exclusion Criteria: Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments Participants who have ever received IBI112 or IL-23 inhibitor History or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances Has any condition that, in the opinion of the investigator, would make participation not be in the best interest of the participant Is pregnant, nursing, or planning a pregnancy (both men and women) within 6 months following the last administration of the study drug
Sites / Locations
- Shanghai Skin Disease HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Group 3
Group 4
Group 6
Group 5
Group 1
Group 2
Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 on week 20 & Dose 1 IBI112 through week 44
Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 through week 44
Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 on week 20 & Dose 1 IBI112 through week 44
Participants receive Dose 1 IBI112 through week 8 & Dose 3 IBI112 on week 20 & placebo through week 44
Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 through week 44
Participants receive Dose 1 IBI112 through week 8 & Dose 2 IBI112 on week 20 & placebo through week 44